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Abstract 
Objective: We evaluated the effectiveness of darunavir (DRV) treatment plus an optimized background regimen in 
120 HIV‑1 treatment‑experienced patients.
Design: Retrospective cohort, multicenter study.
Methods: Adults >16 years with virological treatment failure starting therapy with a DRV‑containing regimen were 
included. Effectiveness was evaluated as the percentage of patients with an undetectable HIV‑1 RNA viral load (<50 
and <200 copies/mL) after 48 weeks, and changes in CD4+ cell counts. We evaluated the risk factors associated with 
treatment failure.
Results: Of the cohort, 83 % were men with a median age of 45 years (interquartile range, IQR 40–51). They had 
experienced treatment for a median of 13 years (IQR 9–17) with a median of six previous regimens (IQR 4–7), all using 
protease inhibitors. After treatment, 82 % (95 % confidence interval, CI 74–88 %) of patients had an HIV‑1 RNA viral 
load <200 copies/mL and 69 % (95 % CI 60–76 %) had <50 copies/mL. The CD4+ cell count increased by 378 cells/
μL (IQR 252–559; P < 0.001 vs. baseline). Risk factors associated with poor outcome were age >40 years [odds ratio, 
OR 0.15 (95 % CI 0.10–0.78); P = 0.015], use of raltegravir in the regimen [OR 0.37 (95 % CI 0.10–0.97); P = 0.046], and 
baseline CD4+ cell count <200 cells/μL [OR 2.79 (95 % CI 1.11–6.97); P = 0.028].
Conclusion: In this Mexican cohort Darunavir was metabolically safe, well tolerated and achieved high rates of viro‑
logical suppression in highly treatment‑experienced patients infected with HIV‑1.
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Background
Virological treatment failure occurs in a significant 
proportion of patients infected with HIV-1, and repre-
sents one of their most challenging health management 
issues. Cohort studies suggest that approximately 10  % 
of patients experience triple-class treatment failure, and 
these rates are increasing with time [1]. Protease inhibi-
tors (PIs) have significantly improved the management 
of HIV infection. However, antiretroviral (ARV) drug 
resistance, including multi-drug and cross-resistance, 
compromises effective long-term therapy. PIs are capa-
ble of providing virological suppression, particularly in 
treatment-experienced patients infected with HIV [2]. 
Combined darunavir/ritonavir (DRV/r) treatment was 
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approved by the U.S Food and Drug Administration in 
June 2006 for use in treatment-experienced patients [3, 
4]. The clinical trials POWER 1 and POWER 2 exposed 
randomized highly treatment-experienced patients to 
DRV/r plus an optimized background regimen (OBR) 
or control PIs (CPI) plus an OBR. At 48 weeks, 61 % of 
patients in the DRV/r arm had a reduction of plasma 
viral load of around 1 log(10) copies/mL versus 15 % in the 
CPI arm [5]. The results of the TITAN study, a large ran-
domized phase III trial in lopinavir-naive, HIV-infected, 
treatment-experienced patients, showed that DRV/r was 
not inferior to lopinavir–ritonavir (LPV/r) therapy, as 
determined by the primary endpoint of <400 copies/mL 
of HIV RNA at week 48. Results of a secondary analysis 
showed that DRV/r was superior to LPV/r at this time 
point [6]. There are few studies in real-life situations. 
Thus, the Swiss Cohort Study reported that as a com-
ponent of therapy for treatment-experienced patients, 
DRV/r could achieve a similar efficacy and tolerability 
in clinical practice to those seen in clinical trials. Clini-
cians should consider whether a patient has failed treat-
ment with both lopinavir and saquinavir and the number 
of failed PI regimens before prescribing darunavir [7]. In 
Brazil, a cohort study was conducted with DRV/r plus an 
OBR and found that it was a highly effective salvage regi-
men under clinical routine conditions [8]. The aim of the 
present study was to evaluate the virological and immu-
nological effectiveness of DRV plus an OBR in a Mexican 




We performed a retrospective study on a cohort of 120 
treatment-experienced HIV-1-infected adults who 
started therapy with a DRV-containing regimen. The 
first endpoint to analyze was an HIV-1 RNA viral load of 
<50 copies/mL after the patients had completed 48 weeks 
of treatment. The secondary endpoint was an HIV-1 
RNA viral load of <200 copies/mL and any increase in the 
CD4+ cell count. Finally, we evaluated the risk factors 
associated with treatment failure in these patients.
Patients
Patients were recruited for HIV treatment from seven 
referral centers of four states in Mexico. Patients were 
>16  years of age with HIV-1 infection confirmed by 
enzyme-linked immunosorbent assay and western blot-
ting, who had virological treatment failure from three 
classes of antiviral drugs, and had mutations detected. 
Patients had been treated previously with at least three 
classes of ARV drugs including nucleoside analog 
reverse-transcriptase inhibitors (NRTIs), non-nucleoside 
reverse-transcriptase inhibitors (NNRTIs), and protease 
inhibitors (PIs). Four patients had a history of integrase 
inhibitor use, with mutation resistance documented for 
each class. Seven patients had been treated unsuccess-
fully with enfuvirtide, but we did not have access to gp41 
genotyping for them.
An individualized OBR was chosen for each patient. 
The regimen included three to four ARV agents, trying to 
use ≥2 fully active drugs according to HIV-1 resistance 
testing and previous ARV drug experience.
Measurements
Clinical histories were recorded regarding ARV regi-
mens, CD4+ cell counts, HIV-1 RNA viral load, and 
serum laboratory parameters at the beginning of the 
therapy with DRV (baseline) and at 48 weeks later. Once 
provided with each patient’s genotype, tropism-testing 
and previous regimens, an expert committee evaluated 
each case to decide the better option for a salvage regi-
men using DRV plus an OBR, considering the previous 
use of ARV regimens.
Mutations were assessed from plasma HIV-1 pol 
sequences using the Stanford HIV Drug Resistance Data-
base (HIVdb; http://hivdb.stanford.edu). The presence of 
resistance was defined according to the Stanford HIVdb 
sensitivity score (SS) ranges as follows: 0–9 =  suscepti-
ble; 10–14 = potential low-level resistance; 15–29 = low-
level resistance; 30–59  =  intermediate resistance; and 
≥60 = high-level resistance.
The genotypic SS (GSS) was defined as the total num-
ber of drugs (excluding darunavir) in a participant’s OBR 
ARV regimen to which their HIV isolate had genotypic 
sensitivity, as deduced from gene sequence and mutation 
analyses. This was calculated based on the drug resist-
ance scores extracted from the Stanford HIVdb. Each 
ARV drug was assigned a score according to the five-level 
Stanford HIVdb interpretation. The sum of the individual 
scores for specific drugs provided the total GSS of that 
treatment, where 0–9 =  1, 10–14 =  0.75, 15–29 =  0.5, 
30–59 =  0.25 and >60 =  0. We classified the total GSS 
score in the following categories: 0–1, 1–2, or ≥2. The 
0–1 group contains viral sequences almost entirely resist-
ant to the drugs in the OBR regimen, and the ≥2 group 
contains viral sequences susceptible to more than two 
drugs given in the regimen [9].
The effectiveness of DRV treatment was evaluated 
based on the percentages of patients with an undetect-
able HIV-1 RNA viral load after 48 weeks of treatment. 
We also evaluated changes in CD4+ cell counts. We 
analyzed the resistance-associated mutations (RAMs) 
associated with DRV at baseline, OBR GSS and the DRV 
Stanford Score for potential risk factors of virological 
treatment failure. Evaluations of metabolic safety were 
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based on changes in fasting lipid levels (total cholesterol 
and triglycerides), and creatinine from baseline to week 
48.
Statistical analysis
Baseline characteristics were summarized using medians 
and interquartile ranges (IQRs) for continuous variables, 
and proportions for categorical variables. Nonparamet-
ric paired tests were used to evaluate changes in CD4+ 
cell counts and HIV-1 RNA viral load. Descriptive statis-
tics were used to evaluate changes in CD4+ cell counts 
and HIV-1 RNA viral load from baseline. For continuous 
variables, we calculated medians with IQRs. For categori-
cal variables, we calculated the number of values in each 
category and the percentages of the values with regard to 
the number of patients. Explorative statistical methods 
were used regarding the efficacy endpoints and changes 
in safety-relevant laboratory parameters. Significant 
changes from baseline were tested using the Wilcoxon 
signed-rank test. We calculated the 95  % confidence 
interval (CI) for appropriate results.
Baseline differences between patients who reached or 
did not reach a viral load of <50  copies/mL at week 48 
were tested using bivariate analysis, which included 
crude odds ratios (ORs), Fisher’s exact and Chi squared 
tests. Independent risk factors associated with virological 
response at week 48 were identified in the multivariate 
logistic regression analysis that included variables from 
bivariate analysis. All analyses were carried out using 
SPSS software (IBM Corp. Released 2010. IBM SPSS Sta-
tistics for Windows, Version 19.0. Armonk, NY, USA: 
IBM Corp.).
Results
A total of 136 multidrug-experienced patients who 
started a DRV/r-based salvage therapy between 2009 and 
2013 were identified. Ten were excluded because they had 
incomplete data in the files. Four patients experienced 
rashes at the beginning of the regimen and they were not 
considered for the analysis; two patients changed their 
institution and we did not have any follow-up data for 
them. Thus, we finally included 120 patients who were 
followed through the 48-week retrospective analyses. The 
median age of the overall cohort at DRV initiation was 
45 years (IQR 40–51) and 83 % were men. Center of Dis-
ease Control Class C AIDS was found in 68 % of patients 
and the median number of previous ARV treatments was 
six (IQR 4–7). All patients had experience of prior PI use, 
most with indinavir, saquinavir/ritonavir and lopinavir/
ritonavir (Table 1).
The primary endpoint was achieved in 69.2  % of 
patients (95 % CI 60–76 %) and the secondary endpoint 
in 82.5  % (95  % CI 74–88  %). At baseline, the median 
HIV-1-RNA viral load was 22,600 copies/mL (4.35 log(10)) 
with an IQR of 3590–75,797 copies/mL (3.5–4.8 log(10)). 
After 48  weeks of treatment, 69  % of patients (n =  83) 
had an HIV-1 RNA viral load of <50 copies/mL and 82 % 
(n = 98) had <200 copies/mL. The median was <50 cop-
ies/mL (<1.6 log(10)) with an IQR of <50–<85 copies/mL 
(<1.6–<1.9 log(10)) in both cases (P < 0.001 compared with 
baseline). At baseline, the median and IQR values for the 
CD4+ cell counts were 245 cells/μL (129–400 cells/μL), 
whereas at weeks 24 and 48 the values were 311 cells/μL 
(239–522 cells/μL) and 378 cells/μL (252–559 cells/μL), 
respectively. These increases were both statistically sig-
nificant (P < 0.001).
The median GSS of the OBR for all patients was 1.5 
(IQR 1.2–2.0). Forty-four (36.6  %) patients had a GSS 
Table 1 Baseline patient characteristics and  optimized 
background
ALT alanine transaminase, DRV darunavir, ENF enfuvirtide, ETV etravirine, 
GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL 
raltegravir, RAM resistance‑associated mutation, TDF tenofovir
a Values are medians with (interquartile ranges), unless indicated otherwise
b Genotypic score according to the Stanford HIVdb
Characteristics Valuesa
Age, years 45 (40–51)
Male gender, n (%) 102 (85 %)
Number of previous regimens 6 (4–7)
Years of experienced treatment 13 (9–17)
Baseline HIV‑1 plasma viral load, log10 copies/mL 4.35 (3.55–4.66)
Baseline HIV‑1 RNA >100,000 copies/mL, n (%) 24 (20 %)
Baseline CD4+ cell counts (cells/μL) 245 (129–400)
Baseline CD4+ cells count <200 cells/μL, n (%) 45 (37.5)
Number of mutations to DRV 1 (0–2)
Number of mutations to DRV ≥2 47 (39 %)
Number of PI RAMs, non‑DRV RAMs 4 (3–6)
GSSb for DRV 0.75 (0.5–1.0)
GSSb for OBR 1.5 (1.2–2.0)
TDF in regimen, n (%) 77 (64.2 %)
MVC in regimen, n (%) 13 (10.8 %)
ENF in regimen, n (%) 13 (10.8 %)
ETV in regimen, n (%) 33 (27.5 %)
RAL in regimen, n (%) 106 (88.3 %)
Stanford score for TDF 35 (20–55)
Stanford score for ETV 10 (0–30)
Stanford score for DRV 12.5 (0–20)
Glucose (mg/dL) 85 (79–91)
Creatinine (mg/dL) 0.86 (0.70–1.0)
ALT (IU/dL) 30 (19–48)
Total cholesterol (mg/dL) 167 (136–195)
Triglycerides (mg/dL) 186 (135–260)
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≥2 (Table  1). When we analyzed OBRs according to 
the Stanford HIVdb, we did not find significant differ-
ences between the GSS of those OBRs with treatment 
failure and those with <50 copies/mL. The median GSS 
for DRV according to the Stanford HIVdb was 12.5 (IQR 
0–20).
The most frequent RAMs for DRV were L33F (35  %), 
I84V (33 %), L10F (18 %), V32I (7 %) and V11I (5 %). We 
were not able to find any relationship between the num-
ber of DRV mutations and virological failure (Table 2).
The most common regimens associated with DRV/r 
were: tenofovir disoproxil fumarate (TDF)  +  raltegra-
vir (RAL) (40  %), etravirine (ETV) +  RAL (14.2  %) and 
TDF + ETV + RAL (6.5 %); the remaining regimens were 
used in 5 % or fewer of the patients. When we evaluated 
the risk factors for virological failure, we found that the 
association of DRV/r with some drugs increased the risk 
of failure but some drugs decreased it (Tables 3, 4).
After applying a logistic regression model the fol-
lowing factors remained significant for the outcome of 
HIV-1 RNA <50 copies/mL: age >40 years [OR 0.15 (95 % 
CI 0.10–0.78); P =  0.015], the use of RAL in a regimen 
[OR 0.37 (95  % CI 0.10–0.97); P  =  0.046], and CD4+ 
cell count <200  cells/μL [OR 2.79 (95  % CI 1.11–6.97); 
P = 0.028].
For assessing metabolic safety, fasting lipid profiles of 
total cholesterol (TC), and triglycerides (TG) were meas-
ured and are shown below as medians and IQRs. TC 
showed a significant increase (P  =  0.003) from a base-
line of 167 mg/dL (136–195 mg/dL) to 174 mg/dL (156–
214  mg/dL) at week 24, and it remained significant at 
48 weeks at 185 mg/dL (150–214 mg/dL; P < 0.001). TG 
showed no significant increase from a baseline of 186 mg/
dL (135–260 mg/dL) to 197 mg/dL (148–271 mg/dL) at 
week 24, and it remained not significant at 48  weeks at 
220 mg/dL (162–305 mg/dL) (Table 5).
Discussion
This study has shown the feasibility of achieving good 
virological and immunological responses with DRV/r 
plus an OBR among highly ARV-experienced HIV-
infected patients under routine clinical care, based on 
a multicenter cohort in Mexico. This particular setting 
allowed the evaluation of DRV/r under ‘real-life’ condi-
tions. We found that a CD4+ cell count <200  cells/μL 
was associated with treatment failure, and the use of RAL 
in the regimen and age >40  years were associated with 
treatment success by achieving an HIV-1 RNA viral load 
of <50 copies/mL. In contrast, age >40 years was signifi-
cantly associated with success, and TDF in the regimen 
was associated with failure leading to an HIV-1 RNA 
viral load of <200 copies/mL. Regarding metabolic safety, 
we had an increase in the TC levels after starting the new 
regimen but not in TGs.
We observed that 69 % of patients reached a viral load 
of <50  copies/mL at week 48. This outcome was better 
than some other randomized clinical trials [5], but was 
similar to the TITAN6 and ODIN studies at 48 weeks 
[10] and some observational studies [11, 12].
The concurrent use of RAL has been associated with a 
favorable treatment outcome. Some trials have found a 
synergistic effect such as the BENCHMRK clinical trial, 
where the coadministration of RAL and DRV/r improved 
the outcomes [13]. In that trial, HIV-1 RNA levels of 
<50  copies/mL were achieved at 48  weeks in 47  % of 
recipients of DRV/r plus an OBR, compared with 69  % 
of patients who received RAL and DRV/r plus an OBR; 
however, when we evaluated other drugs such as enfu-
virtide (ENF) and maraviroc (MVC), we did not find the 
same result. Another observational study found that the 
concomitant use of RAL was strongly associated with 
treatment success [11].
Given that an OBR that included TDF was found to 
increase the risk of treatment failure, we found that an 
intermediate resistance for TDF in the SS (>35) was also 
associated with virological failure [OR 3.6 (95 % CI 1.17–
11.00); P = 0.017] and 45 of the patients were using TDF 
with a high level of resistance. M41L was the most frequent 
mutation in our patients with intermediate or high level 
resistance, and this was associated with an increase in the 
risk of virological treatment failure in another study [14].
We found that age <40 years was associated with a better 
response that was attributed to a better adherence in this 
age group. A meta-analysis showed that older age reduces 
the risk for nonadherence by 25 % in short-term (relative 
risk, RR 0.75; 95 % CI 0.64–0.87) and 35 % in longer-term 
assessments (RR 0.65, 95 % CI 0.50–0.85) [15].
This is the first multicenter cohort in Mexico that has 
evaluated the effectiveness of DRV in highly treatment-
experienced patients; a strength of this study was that 
Table 2 Darunavir resistance mutations (n = 120)
Mutation n (%)
L33F 42 (35 %)
I84V 40 (33 %)
L10F 22 (18 %)
I47V 12 (10 %)
V32I 9 (7 %)
V11I 7 (5 %)
I50V 5 (4 %)
T74P 5 (4 %)
L76V 5 (4 %)
L89V 5 (4 %)
I54M 3 (2 %)
I54L 2 (1 %)
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we could evaluate risk factors for virological treatment 
failure. By contrast, one of the limitations of this study 
is that it was a retrospective method to study previously 
enrolled patients. In addition, we were not able to estab-
lish adverse events associated with DRV. Another limita-
tion of this study is that we could not assess adherence to 
ARV drugs in our population.
Conclusions
These results suggest that the use of DRV/r-based regi-
mens for salvage therapy is an effective strategy in the 
clinical care setting of a developing country. DRV/r in 
combination with RAL increased the overall success as 
a regimen for salvage therapy in these highly ARV treat-
ment-experienced HIV-infected patients. Finally, the 
Table 3 Bivariate and multivariate analysis of risk factors associated with a virological outcome of HIV-1 RNA <50 copies/
mL at week 48 of antiretroviral treatment
DRV darunavir, ENF enfuvirtide, ETV etravirine, GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL raltegravir, RAM resistance‑associated 
mutation, TDF tenofovir
Risk factor Bivariate Multivariate
OR unadjusted 95 % CI P OR adjusted 95 % CI P
Male gender 1.14 0.39–3.32 0.803
Age >40 years 0.35 0.14–0.88 0.023 0.28 0.10–0.78 0.015
Duration of ART >14 years 0.69 0.31–1.50 0.350
Number of previous regimens ≥6 0.97 0.36–2.62 0.963
Baseline HIV‑1 RNA >100,000 copies/mL 2.84 1.13–7–13 0.023 2.10 0.74–5.90 0.158
Baseline CD4+ cell count <200 cells/μL 2.72 1.22–6–06 0.012 2.79 1.11–6.97 0.028
Number of mutations to DRV ≥2 0.922 0.41–2.04 0.842
GSS in OBR <1 vs. ≥1 1.028 0.97–1.08 0.308
GSS in OBR ≤1 vs. >1 1.820 0.56–5.91 0.235
GSS in OBR <2 vs. ≥2 0.863 0.38–1.93 0.721
TDF in regimen 1.48 0.64–3.40 0.236
MVC in regimen 0.64 0.16–2.49 0.521
ENF in regimen 2.99 0.93–9.64 0.057
ETV in regimen 0.790 0.32–1.92 0.603
RAL in regimen 0.28 0.09–0.88 0.023 0.37 0.10–0.97 0.046
Table 4 Bivariate and multivariate analysis of factors associated with an outcome of HIV-1 RNA <200 copies/mL at week 
48 of antiretroviral treatment
DRV darunavir, ENF enfuvirtide, ETV etravirine, GSS genotypic susceptibility score, MVC maraviroc, PI protease inhibitor, RAL raltegravir, RAM resistance‑associated 
mutation, TDF tenofovir
Risk factor OR unadjusted 95 % CI P OR adjusted 95 % CI P
Male gender 2.06 0.64–6.60 0.179
Age >40 years 0.23 0.08–0.66 0.004 0.15 0.04–0.52 0.003
Duration of ART >14 years 0.55 0.21–1.43 0.218
Number of previous regimens ≥6 1.40 0.45–4.33 0.372
Baseline HIV‑1 RNA >100,000 copies/mL 3.19 1.13–8.94 0.022 2.83 0.80–9.94 0.103
Baseline CD4+ cells count <200 cells/μL 2.66 1.02–6.96 0.041 2.65 0.80–8.76 0.109
Number of mutations to DRV ≥2 1.20 0.46–3.12 0.703
GSS in OBR <1 vs. ≥1 1.05 0.95–1.15 0.175
GSS in OBR ≤1 vs. >1 0.759 0.22–2.57 0.435
GSS in OBR <2 vs. ≥2 0.615 0.22–1.72 0.352
TDF in regimen 4.06 1.12–14.7 0.018 4.16 1.02–16.8 0.046
MVC in regimen 1.48 0.37–5.93 0.575
ENF in regimen 1.48 0.37–5.93 0.406
ETV in regimen 0.56 0.17–1.83 0.340
RAL in regimen 0.22 0.06–0.72 0.008 0.32 0.08–1.24 0.101
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use of TDF appears to be a good option except for those 
patients with an SS >35.
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Table 5 Endpoints after 24 and 48 weeks of treatment
* At both 24 and 48 weeks
Outcomes Median (IQR) P
24/48 weeks
Baseline Week 24 Week 48
CD4+ cell count 245 (129–400) 311 (239–522) 378 (252–559) <0.001*
HIV‑1 RNA viral load 22,600 (3590–75,797) <50 (<50–82) <50 (<50–85) <0.001*
Cholesterol (mg/dL) 167 (364–195) 174 (156–214) 185 (150–214) 0.004/<0.001
Triglycerides (mg/dL) 186 (135–260) 197 (148–271) 220 (162–305) 0.465/0.076
Creatinine (mg/dL) 0.86 (0.70–1.0) 0.9 (0.8–1.07) 0.9 (0.8–1.05) <0.001*
